FREE MRSO GBCA Safety & NSF Screening Questions and Answers

Question 1

Which patient condition represents the most significant risk factor for developing Nephrogenic Systemic Fibrosis (NSF)?

Accepted Answer

Acute kidney injury or severe chronic kidney disease

Answer

NSF is a rare but serious condition strongly associated with patients who have impaired renal function. Specifically, those with acute kidney injury (AKI) or severe chronic kidney disease (e.g., GFR < 30 mL/min/1.73m²) are at the highest risk because their kidneys cannot effectively clear the GBCA from the body.

Question 2

According to the ACR Manual on Contrast Media, for which group of patients is a recent eGFR assessment most critical before administering a GBCA?

Accepted Answer

Patients with a history of hypertension, diabetes, or age > 60 years

Answer

The ACR recommends screening for renal dysfunction in patients with known risk factors. These include age over 60, a history of hypertension requiring medical therapy, or a history of diabetes, as these conditions increase the likelihood of underlying chronic kidney disease.

Question 3

GBCAs are classified into groups based on risk. Which group has been associated with the vast majority of documented NSF cases?

Accepted Answer

Group I (Linear agents)

Answer

Group I agents, which have a linear molecular structure, are less stable and more likely to release free gadolinium ions in the body. These agents have been associated with the greatest number of unconfounded, documented cases of NSF, leading to restricted use in many countries.

Question 4

What is the current FDA understanding of gadolinium retention in patients with normal renal function?

Accepted Answer

Trace amounts of gadolinium can be retained in tissues like the brain and bone

Answer

Studies have demonstrated that even in patients with normal kidneys, trace amounts of gadolinium can be retained long-term in various body tissues, most notably the brain (dentate nucleus, globus pallidus) and bone. The long-term clinical significance of this retention is still being investigated.

Question 5

What is the general recommendation regarding the use of GBCAs in pregnant patients?

Accepted Answer

Use only if the diagnostic information is essential and cannot be obtained by other means

Answer

GBCAs are known to cross the placenta and enter the fetal circulation, where the gadolinium is cleared by the fetal kidneys into the amniotic fluid. Due to unknown effects on the fetus, their use is reserved for cases where the diagnostic benefit clearly outweighs the potential risk and the information cannot be obtained otherwise.

MRSO - Magnetic Resonance Safety Officer Practice Test

MRSO - Magnetic Resonance Safety Officer Practice Test

FREE MRSO GBCA Safety & NSF Screening Questions and Answers